Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The global prevalence of blood cancers, including leukemia, lymphoma, and multiple myeloma, continues to rise ... Hoffmann-La Roche Ltd, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., ...

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

An obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of ...

In February, Takeda signed an MoU on rare diseases with the Medical Services Administration under the Ministry of Health, in ...

with an initial rollout expected for phase 3 tests of Sanofi’s multiple sclerosis meds. Here’s how the tool is designed: ...

My thesis argues that Sanofi is a buy today. I think the driving factor of this thesis with the greatest weight to my buy ...